ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective

Press release

ADOCIA annonce que l’essai de phase 2 avec M1Pram a atteint son objectif principal de perte de poids des personnes en surpoids atteintes de diabète de type 1

• Demonstrated weight loss vs. Humalog® (-2.13kg) over 4 months with progressive and continuous weight loss still ongoing at the end of study period.
• Both treatments were well tolerated and overall good glycemic control is maintained in both groups
• Better control of appetite expressed in patient satisfaction scoring after 16 weeks of treatment (82.4% with M1Pram vs. 43.2% with Humalog®)
• Selected for an oral communication at EASD 2022 (European Association for the Study of Diabetes)

Read the press release